The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

(2011) S.-J. Chen et al.   BLOOD

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

(2011) E. Goto et al.   BLOOD

Arsenic Exposure and Toxicology: A Historical Perspective

(2011) Michael F. Hughes et al.   TOXICOLOGICAL SCIENCES

Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein

(2010) P. Isakson et al.   BLOOD

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Subcellular distribution of nuclear import-defective isoforms of the promyelocytic leukemia protein

(2010) Åsne Jul-Larsen et al.   BMC MOLECULAR BIOLOGY

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

A Phase I Study of 5-Fluorouracil/Leucovorin and Arsenic Trioxide for Patients with Refractory/Relapsed Colorectal Carcinoma

(2010) B. Ardalan et al.   CLINICAL CANCER RESEARCH

PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication

(2010) D. Cuchet et al.   JOURNAL OF CELL SCIENCE

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

PML Regulates Apoptosis at Endoplasmic Reticulum by Modulating Calcium Release

(2010) C. Giorgi et al.   SCIENCE

PML Nuclear Bodies

(2010) V. Lallemand-Breitenbach et al.   Cold Spring Harbor Perspectives in Biology

Cell-cycle regulation and dynamics of cytoplasmic compartments containing the promyelocytic leukemia protein and nucleoporins

(2009) A. Jul-Larsen et al.   JOURNAL OF CELL SCIENCE

Lentiviral Vectors and Protocols for Creation of Stable hESC Lines for Fluorescent Tracking and Drug Resistance Selection of Cardiomyocytes

(2009) Hiroko Kita-Matsuo et al.   PLoS One

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Live Cell Dynamics of Promyelocytic Leukemia Nuclear Bodies upon Entry into and Exit from Mitosis

(2008) Yi-Chun M. Chen et al.   MOLECULAR BIOLOGY OF THE CELL

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation

(2008) Michael H. Tatham et al.   NATURE CELL BIOLOGY

Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway

(2008) Valérie Lallemand-Breitenbach et al.   NATURE CELL BIOLOGY

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE

Arsenic trioxide in environmentally and clinically relevant concentrations interacts with calcium homeostasis and induces cell type specific cell death in tumor and non-tumor cells

(2008) Ana-Maria Florea et al.   TOXICOLOGY LETTERS

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

(2007) E. Fox et al.   BLOOD